ARCT vs. CNXC

Last updated Apr 2, 2026

Compare and contrast key facts about Arcturus Therapeutics Holdings Inc. (ARCT) and Concentrix Corporation (CNXC).

Performance

ARCT vs. CNXC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcturus Therapeutics Holdings Inc. (ARCT) and Concentrix Corporation (CNXC). The values are adjusted to include any dividend payments, if applicable.

ARCT vs. CNXC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ARCT Arcturus Therapeutics Holdings Inc.	28.06%	-63.88%	-46.18%	85.91%	-54.17%	-14.68%	-27.87%
CNXC Concentrix Corporation	-35.50%	-1.39%	-55.03%	-25.36%	-24.91%	81.22%	23.38%

Fundamentals

Market Cap ARCT : $214.98M CNXC : $1.63B
EPS ARCT : $0.37 CNXC : -$21.23
PS Ratio ARCT : 2.73 CNXC : 0.17
PB Ratio ARCT : 1.00 CNXC : 0.58
Total Revenue (TTM) ARCT : $78.24M CNXC : $9.95B
Gross Profit (TTM) ARCT : $97.08M CNXC : $3.27B
EBITDA (TTM) ARCT : -$67.83M CNXC : -$944.68M

Returns By Period

In the year-to-date period, ARCT achieves a 28.06% return, which is significantly higher than CNXC's -35.50% return.

ARCT

• 1D: 1.68%
• 1M: -5.99%
• YTD: 28.06%
• 6M: -61.67%
• 1Y: -16.76%
• 3Y*: -31.07%
• 5Y*: -27.98%
• 10Y*: —

CNXC

• 1D: -2.89%
• 1M: -16.37%
• YTD: -35.50%
• 6M: -43.96%
• 1Y: -49.38%
• 3Y*: -38.43%
• 5Y*: -28.06%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ARCT vs. CNXC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARCT

ARCT Risk / Return Rank: 35
ARCT Sharpe Ratio Rank: 32
ARCT Sortino Ratio Rank: 41
ARCT Omega Ratio Rank: 42
ARCT Calmar Ratio Rank: 30
ARCT Martin Ratio Rank: 31

CNXC

CNXC Risk / Return Rank: 8
CNXC Sharpe Ratio Rank: 7
CNXC Sortino Ratio Rank: 10
CNXC Omega Ratio Rank: 10
CNXC Calmar Ratio Rank: 9
CNXC Martin Ratio Rank: 3

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARCT vs. CNXC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT) and Concentrix Corporation (CNXC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ARCT	CNXC	Difference
Sharpe ratio Return per unit of total volatility	-0.18	-0.84	+0.66
Sortino ratio Return per unit of downside risk	0.47	-1.06	+1.53
Omega ratio Gain probability vs. loss probability	1.07	0.86	+0.21
Calmar ratio Return relative to maximum drawdown	-0.35	-0.86	+0.51
Martin ratio Return relative to average drawdown	-0.57	-1.77	+1.20
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ARCT vs. CNXC - Sharpe Ratio Comparison

The current ARCT Sharpe Ratio is -0.18, which is higher than the CNXC Sharpe Ratio of -0.84. The chart below compares the historical Sharpe Ratios of ARCT and CNXC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ARCT	CNXC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.18	-0.84	+0.66
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.30	-0.60	+0.29
Sharpe Ratio (All Time) Calculated using the full available price history	-0.12	-0.35	+0.24

Correlation

The correlation between ARCT and CNXC is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ARCT vs. CNXC - Dividend Comparison

ARCT has not paid dividends to shareholders, while CNXC's dividend yield for the trailing twelve months is around 5.21%.

	TTM	2025	2024	2023	2022	2021
ARCT Arcturus Therapeutics Holdings Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
CNXC Concentrix Corporation	5.21%	3.27%	2.87%	1.15%	0.77%	0.14%

Drawdowns

ARCT vs. CNXC - Drawdown Comparison

The maximum ARCT drawdown since its inception was -95.23%, which is greater than CNXC's maximum drawdown of -87.10%. Use the drawdown chart below to compare losses from any high point for ARCT and CNXC.

Drawdown Indicators

	ARCT	CNXC	Difference
Max Drawdown Largest peak-to-trough decline	-95.23%	-87.10%	-8.13%
Max Drawdown (1Y) Largest decline over 1 year	-74.53%	-59.31%	-15.22%
Max Drawdown (5Y) Largest decline over 5 years	-89.87%	-87.10%	-2.77%
Current Drawdown Current decline from peak	-93.65%	-86.10%	-7.55%
Average Drawdown Average peak-to-trough decline	-72.39%	-46.34%	-26.05%
Ulcer Index Depth and duration of drawdowns from previous peaks	45.61%	28.74%	+16.87%

Volatility

ARCT vs. CNXC - Volatility Comparison

The current volatility for Arcturus Therapeutics Holdings Inc. (ARCT) is 19.84%, while Concentrix Corporation (CNXC) has a volatility of 30.37%. This indicates that ARCT experiences smaller price fluctuations and is considered to be less risky than CNXC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARCT	CNXC	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.84%	30.37%	-10.53%
Volatility (6M) Calculated over the trailing 6-month period	84.31%	49.07%	+35.24%
Volatility (1Y) Calculated over the trailing 1-year period	95.50%	59.06%	+36.44%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	92.15%	47.28%	+44.87%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	103.28%	49.53%	+53.75%

Financials